APOE and Alzheimer disease: During the preclinical phase of AD, carriers of the ApoE4 allele increase cerebral amyloid deposition at an earlier age and do so faster than non-carriers (Grimmer et al., 2010; Morris et al., 2010; Risacher et al., 2013; Bussy et al., 2019).